Ann: Strong growth and expansion of footprint into China, page-9

This is a huge expansion plan into China and SE Asia moving forward on top of the medical cannibis import license (which only 7 entities in Australia have achieved). Moving very fast forwards.

Key for me in this update is that BDA have achieved $300k revenue YTD only for this quarter. So if I extrapolate to the end of this quarter I anticipate revenue to be ~$400k.

If you look at current forecast expenditure for this quarter of $571k. BDA is teethering on cashflow positive which makes BDA a self sustaining entity. I am anticipating cashflow positive over the following two quarters or earlier. 56% profit margin is huge for any product. This plays well to maintaining our capital structure and hopefully much higher prices and valuations.



Costs are maintained well by the BDA management team.

Then you look at peer market comparison below and one would think BDA has significant upside potential to peer valuation average.



Looking forward to FY2018.